在患者中减少GABAAR电流响应的de novoCLPTM1变体
Nana Liu1,2,3, Jinliang Li4, Kai Gao1,2,3,5
1Department of Pediatrics, Peking University First Hospital, Beijing, China.
Epilepsia
|August 14, 2023
概括
在CLPTM1基因中的新de novo变异与有关. 这些变体损害GABA (A) 受体功能,可能促进大脑过度兴奋,并提供新的治疗点.
科学领域:
- 神经遗传学 神经遗传学
- 分子神经科学 分子神经科学
背景情况:
- 是一种慢性神经系统疾病,其特点是经常性发作.
- 遗传因素在病的病因学中发挥着重要作用,新的变种越来越多地被确定为病因.
研究的目的:
- 研究与相关的CLPTM1基因变异的临床特征和致病机制.
- 通过全外因组测序数据分析,识别与相关的新型遗传变异.
主要方法:
- 重新分析了基于三组的全外因子测序数据,以确定新变异.
- 使用表达突变CLPTM1补充DNA的HEK细胞进行了体外功能研究.
- 使用全细胞电压和外外补丁记录来评估GABA (A) 受体功能.
主要成果:
- 确定了两个与相关的CLPTM1 (p.R454H和p.R568Q) 的新发错误变异.
- 证明这些CLPTM1变体降低GABA (A) 受体电流幅度和电荷转移.
- 观察到改变了p.R568Q变异的GABA(A) 受体γ2亚单元的脱敏/失活动力学和表面表达的减少.
结论:
- 这项研究报告了第一个功能相关的新型CLPTM1变体.
- 已识别的变体损害GABA (A) 受体功能,可能导致神经元过激和.
- 这些发现提供了对CLPTM1相关的分子机制的洞察,并提出了潜在的治疗途径.
相关概念视频
Antiepileptic Drugs: GABAergic Pathway Potentiators
461
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
461
Antiepileptic Drugs: Glutamate Antagonists
422
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
422
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
346
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
346
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.3K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.3K
Antiepileptic Drugs: Potassium Channel Activators
212
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
212
Antiepileptic Drugs: Sodium Channel Blockers
667
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
667


